Nader Al-Shakarchi

Nader Al-Shakarchi

Auto-generated profile, based on publicly available information

Nader Al-Shakarchi

Mayo Clinic

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2020 in Heart
Verified
Journal Article
Open access
PDF file
NANader James Al-Shakarchi
Nader James Al-Shakarchi
HEHannah Evans
Hannah Evans
SLSerena A Luchenski
Serena A Luchenski
ASAlistair Story
Alistair Story
ABAmitava Banerjee
Amitava Banerjee
Objectives: To identify: (i) risk of cardiovascular disease (CVD) in homeless versus housed individuals and (ii) interventions for CVD in homeless populations. Methods: We conducted a systematic literature review in EMBASE until December 2018 using a search strategy for observational and interventional studies without restriction regarding languages or countries. Meta-analyses were conducted, where appropriate and possible. Outcome measures were all-cause and CVD mortality, and morbidity. Results: Our search identified 17 articles (6 case-control, 11 cohort) concerning risk of CVD and none regarding specific interventions. Nine were included to perform a meta-analysis. The majority (13/17, 76.4%) were high quality and all were based in Europe or North America, including 765 459 individuals, of whom 32 721 were homeless. 12/17 studies were pre-2011. Homeless individuals were more likely to have CVD than non-homeless individuals (pooled OR 2.96; 95% CI 2.80 to 3.13; p<0.0001; heterogeneity p<0.0001; I2=99.1%) and had increased CVD mortality (age-standardised mortality ratio range: 2.6–6.4). Compared with non-homeless individuals, hypertension was more likely in homeless people (pooled OR 1.38–1.75, p=0.0070; heterogeneity p=0.935; I2=0.0%). Conclusions: Homeless people have an approximately three times greater risk of CVD and an increased CVD mortality. However, there are no studies of specific pathways/interventions for CVD in this population. Future research should consider design and evaluation of tailored interventions or integrating CVD into existing interventions.

29 May 2024 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
IHIkram U. Haq
Ikram U. Haq
NANadia Akhiyat
Nadia Akhiyat
NANader Al-Shakarchi
Nader Al-Shakarchi
KSKonstantinos Siontis
Konstantinos Siontis
SMSiva K. Mulpuru
Siva K. Mulpuru
AKAmmar M. Killu
Ammar M. Killu

24 March 2023 in Medical Teacher
Verified
Journal Article
Closed access
DMDouglas G. J. McKechnie
Douglas G. J. McKechnie
NANader Al-Shakarchi
Nader Al-Shakarchi
STSean A. Tackett
Sean A. Tackett
TYTim M. Young
Tim M. Young
MRMohammed A. Rashid
Mohammed A. Rashid
Prior studies report that most published medical education research is unfunded. We sought to determine the extent and sources of funding for medical education research articles published in leadin...

7 July 2023 in Mayo Clinic Proceedings: Digital Health
Verified
Journal Article
Open access
NANader James Al-Shakarchi
Nader James Al-Shakarchi
IHIkram U. Haq
Ikram U. Haq

16 April 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JSJulian Surey
Julian Surey
MVMartha Veitch
Martha Veitch
SRSally Rogers
Sally Rogers
NSNader Al Shakarchi
Nader Al Shakarchi
SBStan Burridge
Stan Burridge
ABAmitava Banerjee
Amitava Banerjee

18 November 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
AAAlberto Aimo
Alberto Aimo
Martina NestiMartina Nesti
Martina Nesti
GVGiuseppe Vergaro
Giuseppe Vergaro
AKAmmar M. Killu
Ammar M. Killu
DBDimitrios Bampatsias
Dimitrios Bampatsias
MEMichele Emdin
Michele Emdin
Background: Transthyretin amyloid cardiomyopathy (ATTR‐CM) has a specific pathophysiology, with myocardial stiffening and systolic dysfunction only in advanced stages. We aimed to investigate the response to cardiac resynchronization therapy (CRT) in ATTR‐CM compared with heart failure. Methods: In this multicenter, observational study, patients with ATTR‐CM receiving CRT (n=101) were matched to patients without amyloid cardiomyopathy by sex, age, and implantation type (CRT with versus without defibrillator versus conduction system pacing, upgrade versus first implant). We evaluated changes in QRS duration and echocardiographic parameters following CRT implantation and at the most recent available assessments. The study end points were all‐cause death alone or combined with heart failure hospitalization. Results: Patients with ATTR‐CM (median age, 76 [interquartile range, 72–83] years, 98% men, left ventricular (LV) ejection fraction 30% [26–33]) showed greater QRS shortening after CRT implantation ( P =0.012), but not after a median of around 1 year ( P =0.152). There were no significant differences in the absolute LV ejection fraction changes immediately after implantation (+7 [+2/+10] versus +3 [0/+9] units; P =0.124), or to the last echo ( P =0.796), which was performed after 1.3 years in patients with ATTR‐CM and 2.9 years in patients without amyloid cardiomyopathy. Patients with ATTR‐CM had a shorter survival than controls ( P <0.001 for both end points). Patients with ATTR‐CM experiencing an early improvement in LV ejection fraction had a longer survival (log‐rank, 4.3; P =0.038). Conclusions: Following CRT implantation, patients with ATTR‐CM show QRS narrowing and improvement in LV ejection fraction, not different from patients without amyloid cardiomyopathy. Early favorable LV remodeling seems to be associated with a lower risk of all‐cause death.